Download PDF
Exp Clin Endocrinol Diabetes 2008; 116: S26-S29
DOI: 10.1055/s-2008-1081484
Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Mucosal Insulin Vaccination for Type 1 Diabetes Prevention

E. Bonifacio 1 , P. Achenbach 2 , L. Pan 2 , A.-G. Ziegler 2
  • 1CRTD, Dresden University of Technology, Dresden, Germany
  • 2Diabetes Research Institute, Munich, Germany
Further Information

Publication History

received 29.04.2008

accepted 20.05.2008

Publication Date:
05 September 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Mucosal administration of autoantigen, if efficacious, is an attractive therapeutic approach for prevention of type 1 diabetes. It can prevent or delay autoimmune diabetes in animal models, but although shown to be safe has not yet been proven effective in human studies. Efficacy may depend upon the dose and route at which antigen is administered, the stage in type 1 diabetes pathogenesis at which treatment is initiated, and the study cohort that is treated. Here we address these issues and propose a clinical translation possibility for mucosal insulin administration in genetically at risk individuals.

Key words

insulin - oral vaccination - intranasal insulin - type 1 diabetes - autoimmunity - autoantigen - mucosal immunity - genetic prediction of type 1 diabetes

References

  • 1 French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M, Silva A, Georgiou HM, Kay TW, Harrison LC, Lew AM. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice.  Diabetes. 1997;  46 34-39
    CrossrefPubMedGoogle Scholar
  • 2 Thebault-Baumont K, Dubois-Laforgue D, Krief P, Briand JP, Halbout P, Vallon-Geoffroy K, Morin J, Laloux V, Lehuen A, Carel JC, Jami J, Muller S, Boitard C. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice.  J Clin Invest. 2003;  111 851-857
    CrossrefPubMedGoogle Scholar
  • 3 Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse.  Proc Natl Acad Sci USA. 2003;  100 10376-10381
    CrossrefPubMedGoogle Scholar
  • 4 Jaeckel E, Lipes MA, Boehmer H von. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes.  Nat Immunol. 2004;  5 1028-1035
    CrossrefPubMedGoogle Scholar
  • 5 Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.  Nature. 2005;  435 220-223
    CrossrefPubMedGoogle Scholar
  • 6 Krishnamurthy B, Dudek NL, MacKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.  J Clin Invest. 2006;  116 3258-3265
    CrossrefPubMedGoogle Scholar
  • 7 Vardi P, Ziegler AG, Mathews JH, Dib S, Keller RJ, Ricker AT, Wolfsdorf JI, Herskowitz RD, Rabizadeh A, Eisenbarth GS, Soeldner S. Concentration of insulin autoantibodies at onset of type 1 dia-betes. Inverse log-linear correlation with age.  Diabetes Care. 1988;  11 736-739
    PubMedGoogle Scholar
  • 8 Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study.  Diabetes. 1999;  48 460-468
    CrossrefPubMedGoogle Scholar
  • 9 Kimpimaki T, Kulmala P, Savola K, Kupila A, Korhonen S, Simell T, Ilonen J, Simell O, Knip M. Natural history of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population.  J Clin Endocrinol Metab. 2002;  87 4572-4579
    CrossrefPubMedGoogle Scholar
  • 10 Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).  J Clin Endocrinol Metab. 2004;  89 3896-3902
    CrossrefPubMedGoogle Scholar
  • 11 Colman PG, Steele C, Couper JJ, Beresford SJ, Powell T, Kewming K, Pollard A, Gellert S, Tait B, Honeyman M, Harrison LC. Islet autoimmunity in infants with a type 1 diabetic relative is common but is frequently restricted to one autoantibody.  Diabetologia. 2000;  43 203-209
    CrossrefPubMedGoogle Scholar
  • 12 Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents.  Ann Intern Med. 2004;  140 882-886
    PubMedGoogle Scholar
  • 13 Kimpimaki T, Kupila A, Hamalainen AM, Kukko M, Kulmala P, Savola K, Simell T, Keskinen P, Ilonen J, Simell O, Knip M. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: The finnish type 1 diabetes prediction and prevention study.  J Clin Endocrinol Metab. 2001;  86 4782-4788
    CrossrefPubMedGoogle Scholar
  • 14 Yu L, Robles DT, Abiru N, Kaur P, Rewers M, Kelemen K, Eisenbarth GS. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: evidence for early determination of subsequent diabetes.  Proc Natl Acad Sci USA. 2000;  97 1701-1706
    CrossrefPubMedGoogle Scholar
  • 15 Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro) insulin anticipate the autoimmune cascade that leads to type 1 diabetes.  J Clin Invest. 2004;  114 589-597
    CrossrefPubMedGoogle Scholar
  • 16 Koczwara K, Muller D, Achenbach P, Ziegler AG, Bonifacio E. Identification of insulin autoantibodies of IgA isotype that preferentially target non-human insulin.  Clin Immunol. 2007;  124 77-82
    CrossrefPubMedGoogle Scholar
  • 17 Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health.  J Clin Invest. 2004;  113 451-463
    CrossrefPubMedGoogle Scholar
  • 18 Monti P, Scripoli M, Rigamonti A, Mayr A, Jaeger A, Bonfanti R, Chiumello G, Ziegler AG, Bonifacio E. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes.  J Immunol. 2007;  179 5785-5792
    CrossrefPubMedGoogle Scholar
  • 19 Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.  Nature. 2005;  435 224-228
    CrossrefPubMedGoogle Scholar
  • 20 Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases.  Immunol Today. 1997;  18 335-343
    CrossrefPubMedGoogle Scholar
  • 21 Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease.  Curr Opin Immunol. 2000;  12 704-711
    CrossrefPubMedGoogle Scholar
  • 22 Faria AMC, Weiner HL. Oral tolerance.  Immunol Rev. 2005;  206 232-259
    CrossrefPubMedGoogle Scholar
  • 23 Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes.  J Autoimmun. 1994;  7 655-663
    CrossrefPubMedGoogle Scholar
  • 24 Harrison LC, Dempsey-Collier M, Kramer DR, Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes.  J Exp Med. 1996;  184 2167-2174
    CrossrefPubMedGoogle Scholar
  • 25 Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin.  Proc Natl Acad Sci USA. 1991;  88 10252-10256
    CrossrefPubMedGoogle Scholar
  • 26 Maron R, Melican NS, Weiner HL. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes.  J Autoimmun. 1999;  12 251-258
    CrossrefPubMedGoogle Scholar
  • 27 Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9–23).  Proc Natl Acad Sci USA. 1996;  93 956-960
    CrossrefPubMedGoogle Scholar
  • 28 Herrath MG von, Dyrberg T, Oldstone MB. Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice.  J Clin Invest. 1996;  98 1324-1331
    CrossrefPubMedGoogle Scholar
  • 29 Maron R, Guerau-de-Arellano M, Zhang X, Weiner HL. Oral administration of insulin to neonates suppresses spontaneous and cyclophosphamide induced diabetes in the NOD mouse.  J Autoimmun. 2001;  16 21-28
    CrossrefPubMedGoogle Scholar
  • 30 Kupila A, Sipila J, Keskinen P, Simell T, Knip M, Pulkki K, Simell O. Intranasally administered insulin intended for prevention of type 1 diabetes – a safety study in healthy adults.  Diabetes Metab Res Rev. 2003;  19 415-420
    CrossrefPubMedGoogle Scholar
  • 31 Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, Couper JJ, Colman PG. Pancreatic {beta}-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.  Diabetes Care. 2004;  27 2348-2355
    CrossrefPubMedGoogle Scholar
  • 32 Chaillous L, Lefevre H, Thivolet C, Boitard C, Lahlou N, Atlan-Gepner C, Bouhanick B, Mogenet A, Nicolino M, Carel JC, Lecomte P, Marechaud R, Bougneres P, Charbonnel B, Sai P. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group.  Lancet. 2000;  356 545-549
    CrossrefPubMedGoogle Scholar
  • 33 Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Manca Bitti ML, Matteoli MC, Marietti G, Ferrazzoli F, Cassone Faldetta MR, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII).  IMDIAB Group. Diabetologia. 2000;  43 1000-1004
    CrossrefPubMedGoogle Scholar
  • 34 Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.  Science. 1993;  259 1321-1324
    CrossrefPubMedGoogle Scholar
  • 35 Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. Effects of oral administration of type II collagen on rheumatoid arthritis.  Science. 1993;  261 1727-1730
    CrossrefPubMedGoogle Scholar
  • 36 Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial–Type 1.  Diabetes Care. 2005;  28 1068-1076
    CrossrefPubMedGoogle Scholar
  • 37 Monetini L, Cavallo MG, Sarugeri E, Sentinelli F, Stefanini L, Bosi E, Thorpe R, Pozzilli P. Cytokine profile and insulin antibody IgG subclasses in patients with recent onset Type 1 diabetes treated with oral insulin.  Diabetologia. 2004;  47 1795-1802
    CrossrefPubMedGoogle Scholar
  • 38 Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio E. Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse.  Clin Immunol. 2003;  106 155-162
    CrossrefPubMedGoogle Scholar
  • 39 Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, Herrath M von. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.  J Clin Invest. 2006;  116 1371-1381
    CrossrefPubMedGoogle Scholar
  • 40 Bonifacio E, Hummel M, Walter M, Schmid S, Ziegler AG. IDDM1 and multiple family history of type 1 diabetes combine to identify neonates at high risk for type 1 diabetes.  Diabetes Care. 2004;  27 2695-2700
    CrossrefPubMedGoogle Scholar
  • 41 Aly TA, Ide A, Barker JM, Fernando M, Babu SR, Yu L, Miao D, Erlich HA, Fain P, Barriga K, Norris JM, Eisenbarth GS, Rewers MJ. HLA genotype and haplotype sharing determine extremely high risk of early childhood type 1 diabetes.  PNAS. 2006;  103 14074-14079
    CrossrefPubMedGoogle Scholar
  • 42 Walter M, Albert E, Conrad M. et al . IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of type 1 diabetes and associated autoimmunity.  Diabetologia. 2003;  46 712-720
    PubMedGoogle Scholar
  • 43 Laine AP, Hermann R, Knip M, Simell O, Akerblom HK, Ilonen J. The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population.  Tissue Antigens. 2004;  63 72-74
    CrossrefPubMedGoogle Scholar
  • 44 Barker JM, MacFann KK, Orban T. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.  Diabetologia. 2007;  50 1603-1606
    CrossrefPubMedGoogle Scholar
  • 45 Staeva-Vieira T, Peakman M, Herrath M von. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes.  Clin Exp Immunol. 2007;  148 17-31
    PubMedGoogle Scholar

Correspondence

E. BonifacioPhD 

CRTD, Biotechnology Center

Dresden University of Technology

Tatzberg 47/49

01307 Dresden

Germany

Email: ezio.bonifacio@crt-dresden.de

      >